ImmunityBio reports preliminary Q1 2026 net product revenue $44.2M, up 168% YoY, cash $381M

ImmunityBio, Inc.

Preliminary Q1 2026 net product revenue ~$44.2M, up 168% YoY and 15% sequentially from $38.3M in Q4 2025.
Cash, cash equivalents and marketable securities of $380.9M as of March 31, 2026.
ANKTIVA unit sales volume increased 168% YoY; now approved in 5 jurisdictions covering ~34 countries.
NCCN guidelines updated March 2026 to include ANKTIVA plus BCG for BCG-unresponsive NMIBC papillary-only disease (Category 2A).
Pivotal BCG-naive NMIBC CIS trial (QUILT-2.005) fully enrolled; supplemental BLA submission on track for 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ImmunityBio, Inc. reported the fiscal quarter ending March 31, 2026 results: revenue approximately $44.2 million.

Period: the fiscal quarter ending March 31, 2026
Revenue: approximately $44.2 million
Result: preliminary results

Exact text from the filing

ImmunityBio reported preliminary net product revenue of approximately $44.2 million during the three-month period ending March 31, 2026

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

ImmunityBio, Inc. filing history →

Source: SEC EDGAR

accession 0001326110-26-000036

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.